Mentor Capital has announced that Quantum Immunologics (QI) is beginning its FDA-authorized breast cancer trial, the completion of the first clinical treatment injection.
QI is currently sponsoring and conducting an FDA-authorized phase I/II clinical trial, testing the safety and efficacy of its immunotherapy on 27 stage IV breast cancer patients, who have failed conventional therapy. The first patient in the breast cancer trial has begun to receive QI’s dendritic cell therapy.
Chet Billingsley, CEO of Mentor Capital, said: “The successful initiation of concurrent Phase I/II trials represents an important step in the value equation for QI. Comparing the cost to acquire 20% of other dendritic immunotherapy companies, like Dendreon (DNDN), with Mentor Capital, which holds 20% of QI, will reveal attractive buying opportunities for biotechnology investors, now that QI is at the clinical stage.”
QI’s clinical trial is designed around the use of dendritic cell therapy, which employs oncofetal antigen (OFA) to recruit the patient’s own immune system to target and attack the cancer cells. Each patient will receive three monthly injections of the patient’s own dendritic cells that have been sensitized to OFA.